Solugen closed its Series B funding round and now has $32 million to grow its chemical products. Getty Images

A fast-growing chemicals manufacturer has something to celebrate — 32 million somethings. Solugen Inc., the only producer of bio-based peroxide solutions, announced that its $32 million Series B funding round has closed.

The round was led by San Francisco-based Founders Fund, and Y Combinator, Refactor Capital, Fifty Years, and KdT Ventures all also contributed to the round. Solugen only closed its Series A — a $13.5 million round — just over six months ago.

"Solugen is on track to become a major player in the chemical industry," says Brian Singerman, partner at Founders Fund, in a release. "The company's success to date proves that there is significant demand for cleaner, greener methods of chemical production. For customers, choosing between toxic, petrochemical-based chemicals and cheaper, safer, environmentally friendly bio-chemicals from Solugen is a no-brainer."

The company has created bio-based solutions that are revolutionizing the chemicals industry by making processes more efficient, safer, and cheaper. One product con convert plant sugars into hydrogen peroxide while others can treat, clean, and oxidize water used in industrial contexts. Its first product, Ode to Clean, was sold to Diamond Wipes last year.

According to the release, the company has 10 more products in the works awaiting patent filings and revenue has grown 10 times over in the past year thanks to multiple multi-million dollar contracts. Solugen is has also started construction on a 200,000-square-foot office space that expects to deliver in early 2020.

"This is a momentous landmark in our company's young history, and we want to thank our investors for their support as well as for their belief in our technology, team, and mission of decarbonizing the chemicals industry," says CEO Gaurab Chakrabarti, in a release.

The funds will allow the company to continue to grow its chemical products in order to keep up with client demand.

"Thanks to innovations like this our customers are seeing results that save them a tremendous amount of money, reduce their carbon footprint and minimize the dangers associated with using traditional, often dangerous petrochemical-derived products," Chakrabarti says in the release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.